RecombinantVEGF121, Human

VEGF-A121 is one of five isoforms (121, 145, 165, 189, and 206) of VEGF protein, a cytokine belonging to the Platelet Differentiation Growth Factor (PDGF) family, and existing as a disulfide-linked homodimeric glycoprotein. In contrast to the longer isoforms, VEGF-A121 is more freely diffusible, and cannot bind to heparin. In vivo, VEGF is expressed predominantly in lung, heart, kidney, and adrenal glands, and the expression of VEGF is up-regulated by a number of growth factors, including PDGF, Fibroblast Growth Factor (FGF), Epidermal Growth Factor (EGF), and Tumor Necrosis Factor (TNF) . VEGF signals via binding to two tyrosine kinase receptors: the Fms-like tyrosine kinase 1 (Flt-1) and the kinase domain receptor (KDR) . VEGF is a specific mitogen and survival factor, contributing to abnormal angiogenesis and cancer development. Recombinant human VEGF-A121 (rhVEGF-A121) produced in E.coli is a disulfide-linked homodimer containing two non-glycosylated polypeptide chains of 121 amino acids each. A fully biologically active molecule, rhVEGF-A121 has a molecular mass of 28.2 kDa analyzed by non-reducing SDS-PAGE and is obtained by proprietary chromatographic techniques at GenScript.

Vascular Endothelial Growth Factor121, VPF

Escherichia coli.

< 0.2 EU/μg, determined by LAL method.

> 95% as analyzed by SDS-PAGE and HPLC.

ED50 2x 10ˆ5 units/mg.

Lyophilized after extensive dialysis against PBS.

28.2 kDa, observed by non-reducing SDS-PAGE.

Lyophilized recombinant human VEGF-A121 (rhVEGF-A121) remains stable up to 6 months at -80°C from date of receipt. Upon reconstitution, rhVEGF-A121 remains stable up to 2 weeks at 4°C or up to 3 months at -20°C.

For research use only.

Reconstituted in ddH2O or PBS at 100 μg/ml.

Lyophilized after extensive dialysis against PBS.